Our products are born from the dedication and care we invest in every step of the process. In our nine production lines, we formulate, package and condition with an effort that reflects our commitment to your well-being.
Let’s work hard so that you and your loved ones can enjoy clearer, healthier vision and a healthier life.
Sophia Research Center is dedicated to developing pharmaceutical products of the highest quality and innovation, complying with the strictest industry regulations, such as those established by the FDA and EMA.
Our development policy follows ICH recommendations, and our laboratories are equipped with advanced technology such as gas chromatographs and infrared and UV-VIS spectrophotometers.
Each product is developed based on the Quality by Design concept, ensuring that each phase of development meets the highest quality specifications, resulting in a product that meets all the specifications and/or quality characteristics required for its proper functioning.
The center has a team of highly qualified and committed professionals, supported by state-of-the-art technology, including ultra-high performance liquid chromatographs, mass coupled liquid chromatographs and rheology equipment.
With an infrastructure of 6,520 m2, our center houses analytical control, pharmaceutical development and physicochemical characterization laboratories, all equipped with the best technology available.
1999
1999
Fórmula patentada para prevenir la irritación ocular y facilita la penetración de fórmulas oftálmicas.
1999
1999
Primera lágrima artificial libre de conservadores en unidosis.
2002
2002
Primera ciclosporina en solución acuosa al 0.1% a nivel mundial.
2005
2005
Primer Latanoprost no refrigerable.
2007
2007
Primera triple combinación a nivel mundial de dorzolamida, timolol y brimonidina.
2016
2016
Incursión de una completa línea libre de conservadores.
2016
2016
Primera triple combinación en el mundo de Dorzolamida, Timolol y Brimonidina libre de conservantes, con respaldo científico propio.
2017
2017
Primera doble combinación de Dorzolamida + Timolol libre de conservantes en Latinoamérica.
2023
2023
Única fluoroquinolona oftálmica de tercera generación en Latinoamérica.
2023
2023
Primera solución farmacológica oftálmica de atropina al 0.01% para tratamiento en niños en Latinoamérica.
2024
2024
Primera lágrima artificial con Sistema Nanotech Sophia.
